BRCA1 and ovarian carcinoma: It is observed that this combination is more effective in patients with metastatic TNBC or prostate cancer carrying BRCA1/2 mutations or HRD, while the curative effect is similar between ovarian cancer patients with or without BRCA1/2 mutations or HRD [84,85,86].